Lonza received Swissmedic approval and a GMP license for a new aseptic drug‑product filling line in Stein, Switzerland, optimized for highly potent biologics including ADCs. The line adds liquid and lyophilized vial filling capabilities with advanced containment and isolator technologies meeting Annex 1 requirements, enabling clinical and commercial supply for monoclonal antibodies, bispecifics and ADCs. Lonza said the expansion strengthens its integrated end‑to‑end offering and addresses growing demand for high‑containment drug‑product manufacturing.